The British Journal of Clinical Pharmacology: The first 50 years.

The British Journal of Clinical Pharmacology celebrates its 50th anniversary of publication in 2023. Here four previous Editors-in-Chief and the current Editor reflect on the Journal's history and the changes that have occurred during that time.

Theoretical Analysis of the Pressure Regions Where Adsorption Azeotropes Exist in Binary Gas Mixtures.

This work confirmed theoretically whether adsorption azeotropes can form in a binary gas mixture at a pressure below the intersection pressure of the corresponding single-gas isotherms. The thermodynamically consistent dual-process Langmuir (DPL) model with equal component saturation capacities on site and the general DPL model with nonequal on site were used for this purpose. Relationships derived from both DPL models, in terms of the single-gas isotherm DPL model parameters, were used to answer this question.

Theoretical Analysis of the Necessary and Sufficient Conditions for the Formation of Adsorption Azeotropes in Binary Gas Mixtures.

This work theoretically assessed the necessary and sufficient conditions for the formation of an adsorption azeotrope in a binary gas mixture when this mixture exhibits either intersecting or nonintersecting single gas isotherms. The thermodynamically consistent dual process Langmuir (DPL) model with equal component saturation capacities on site and the general DPL model with nonequal on site were used for this purpose. Analytical expressions derived for both DPL models, in terms of the single gas isotherm DPL model parameters, were used to find examples or to determine theoretically when an adsorption azeotrope forms in a binary gas mixture for both intersecting and nonintersecting single gas isotherms.

A Randomized, Double-Blind, Placebo-Controlled, First-Time-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of GSK3389404 in Healthy Subjects.

GSK3389404 is a liver-targeted antisense oligonucleotide that inhibits synthesis of hepatitis B surface antigen and all other hepatitis B virus proteins. This first-in-human, randomized, double-blind, phase 1 study assessed the safety and pharmacokinetics of GSK3389404 administered subcutaneously (SC) in healthy subjects. Four single ascending-dose cohorts (10 mg, 30 mg, 60 mg, and 120 mg) and 3 multiple ascending-dose cohorts (30 mg, 60 mg, and 120 mg once weekly for 4 weeks) each comprised 6 subjects randomized to GSK3389404 and 2 subjects randomized to placebo.

Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis.

Systemic amyloidosis is a fatal disorder caused by pathological extracellular deposits of amyloid fibrils that are always coated with the normal plasma protein, serum amyloid P component (SAP). The small-molecule drug, miridesap, [(R)-1-[6-[(R)-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-carboxylic acid (CPHPC)] depletes circulating SAP but leaves some SAP in amyloid deposits. This residual SAP is a specific target for dezamizumab, a fully humanized monoclonal IgG1 anti-SAP antibody that triggers immunotherapeutic clearance of amyloid.

Lack of effect of oral cabotegravir on the pharmacokinetics of a levonorgestrel/ethinyl oestradiol-containing oral contraceptive in healthy adult women.

Aims: This study aimed to investigate whether cabotegravir (CAB), an integrase inhibitor in development for treatment and prevention of human immunodeficiency virus-1, influences the pharmacokinetics (PK) of a levonorgestrel (LNG) and ethinyl oestradiol (EO)-containing oral contraceptive (OC) in healthy women.

Methods: In this open-label, fixed-sequence crossover study, healthy female subjects received LNG 0.15 mg/EO 0.

Limitations of Breakthrough Curve Analysis in Fixed-Bed Adsorption.

This work examined in detail the prediction of the axial dispersion coefficient from available correlations versus obtaining both it and mass transfer information from experimental breakthrough data and the consequences that may arise when doing so based on using a 1-D axially dispersed plug flow model and its associated Danckwerts outlet boundary condition. These consequences mainly included determining the potential for erroneous extraction of the axial dispersion coefficient and/or the LDF mass transfer coefficient from experimental data, especially when nonplug flow conditions prevailed in the bed. Two adsorbent/adsorbate cases were considered, i.

Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component.

Background: The amyloid fibril deposits that cause systemic amyloidosis always contain the nonfibrillar normal plasma protein, serum amyloid P component (SAP). The drug (R)-1-[6-[(R)-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-carboxylic acid (CPHPC) efficiently depletes SAP from the plasma but leaves some SAP in amyloid deposits that can be specifically targeted by therapeutic IgG anti-SAP antibodies. In murine amyloid A type amyloidosis, the binding of these antibodies to the residual SAP in amyloid deposits activates complement and triggers the rapid clearance of amyloid by macrophage-derived multinucleated giant cells.

On the use of the dual process Langmuir model for predicting unary and binary isosteric heats of adsorption.

Analytic expressions for unary and binary isosteric heats of adsorption as a function of the adsorbed phase loading were derived from the dual process Langmuir (DPL) model using the Clausius-Clapeyron equation. Unary isosteric heats of adsorption predicted from these expressions for several adsorbate-adsorbent systems were compared to values in the literature predicted from the well-accepted graphical approach using Toth and unilan models (Adsorption Equilibrium Data Handbook; Prentice Hall: NJ, 1989). Predictions from the DPL model were also compared to rare experimental unary and binary isosteric heats of adsorption in the literature for another adsorbate-adsorbent system.